Indication
SARS-CoV-2
30 clinical trials
45 products
2 drugs
Clinical trial
Multicenter, Randomized, Double-Blind, Placebo-Controlled, Proof of Concept Study of LSALT Peptide as Prevention of Acute Respiratory Distress Syndrome (ARDS) and Acute Kidney Injury in Patients Infected With SARS-CoV-2 (COVID-19)Status: Completed, Estimated PCD: 2021-05-27
Product
PlaceboProduct
LSALTProduct
Bivalent BNT162b2Clinical trial
A MASTER PHASE 1/2/3 PROTOCOL TO INVESTIGATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF VARIANT-ADAPTED BNT162b2 RNA-BASED VACCINE CANDIDATE(S) IN HEALTHY CHILDRENStatus: Recruiting, Estimated PCD: 2025-08-11
Product
Variant-adapted BNT162b2Product
BNT162b2Product
LSALT peptideClinical trial
The Safety of EIDD-2801 and Its Effect on Viral Shedding of SARS-CoV-2Status: Completed, Estimated PCD: 2022-02-21
Clinical trial
A Clinical Evaluation of the Safety and Efficacy of Randomized Placebo Versus the 8-aminoquinoline Tafenoquine for Early Symptom Resolution in Patients With Mild to Moderate COVID 19 Disease and Low Risk of Disease Progression (the "ACLR8-LR" Study)Status: Not yet recruiting, Estimated PCD: 2024-04-27
Product
EIDD-2801Product
TafenoquineClinical trial
A Randomised, Double-blind, Placebo-controlled, Phase III Trial to Determine the Efficacy and Safety of Inhaled SNG001 for the Treatment of Patients Hospitalised Due to Moderate COVID-19Status: Completed, Estimated PCD: 2021-12-15
Product
SNG001Product
GLS-1200Clinical trial
Efficacy, Safety, and Tolerability of GLS-1200 Topical Nasal Spray in the Prevention of Incident Confirmed, Symptomatic SARS-CoV-2 InfectionStatus: Terminated, Estimated PCD: 2023-01-10
Clinical trial
Randomized, Phase 2 Clinical Trial to Evaluate the Safety and Efficacy of Masitinib Combined With Isoquercetin, and Best Supportive Care in Hospitalized Patients With Moderate and Severe COVID-19Status: Recruiting, Estimated PCD: 2023-12-01
Product
IsoquercetinProduct
MasitinibProduct
Best Supportive CareClinical trial
A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Proof-Of-Concept Study To Evaluate Efficacy And Safety Of Recombinant Human Plasma Gelsolin (Rhu-pGSN) Added To Standard Of Care In Subjects With Severe Covid-19 PneumoniaStatus: Completed, Estimated PCD: 2021-05-25
Clinical trial
A Phase I/II Randomized Double-blinded Placebo-controlled Clinical Trial to Determine Safety and Feasibility of Using an Acellular Sterile Filtered Amniotic Fluid as a Treatment for COVID-19 PatientsStatus: Completed, Estimated PCD: 2022-08-02
Product
Human Amniotic FluidClinical trial
Treatment of Serious and Critical Patients With COVID-19 With TocilizumabStatus: Active (not recruiting), Estimated PCD: 2024-12-01
Product
TocilizumabClinical trial
Health, Perception, Practices, Relations and Social Inequalities in the General Population During the Covid-19 Crisis - SerologyStatus: Completed, Estimated PCD: 2022-12-31
Product
Non applicableClinical trial
COVID-19: BCG As Therapeutic Vaccine, Transmission Limitation, and Immunoglobulin EnhancementStatus: Completed, Estimated PCD: 2022-06-04
Drug
BCGClinical trial
Interferon Lambda for Immediate Antiviral Therapy at Diagnosis (ILIAD): A Phase II Randomized, Double-blind, Placebo-controlled, Multicenter Trial to Evaluate the Effect of Peginterferon Lambda for the Treatment of COVID-19Status: Completed, Estimated PCD: 2022-08-19
Product
Peginterferon Lambda-1AClinical trial
A Randomized, Double-Blind, Placebo-Controlled Phase IIa Study of Quintuple Therapy to Treat COVID-19 InfectionStatus: Completed, Estimated PCD: 2024-02-27
Product
HydroxychloroquineProduct
AzithromycinClinical trial
Single Donor Banked Bone Marrow Mesenchymal Stromal Cells for the Treatment of COVID-19 Induced ARDS: A Non-Blinded Randomized, Controlled StudyStatus: Completed, Estimated PCD: 2023-01-10
Product
Mesenchymal Stromal CellsClinical trial
Use of COVID-19 Convalescent Plasma in the Patients Infected With COVID-19 (SARS-CoV-2) - Efficacy and SafetyStatus: Completed, Estimated PCD: 2021-05-10
Clinical trial
Comparison of the Efficacy and Safety of Human Coronavirus Immune Plasma (HCIP) vs. Control (SARS-CoV-2 Non-immune) Plasma Among Outpatients With Symptomatic COVID-19Status: Completed, Estimated PCD: 2022-01-14
Product
PlasmaClinical trial
Defibrotide Therapy for SARS-CoV2 Acute Respiratory Distress Syndrome (ARDS)Status: Completed, Estimated PCD: 2021-03-26
Product
DefibrotideClinical trial
Effect of Antiseptic Mouthwash/Gargling Solutions and Pre-procedural Rinse on SARS-CoV-2 Load (COVID-19)Status: Terminated, Estimated PCD: 2022-09-10
Product
Oral-B Mouth SoreClinical trial
Study of Kinetics and Efficacy of the Immune Response Against COVID-19 Among Hospital StaffStatus: Completed, Estimated PCD: 2022-03-15
Product
Blood CollectionProduct
SalivaClinical trial
Experimental Expanded Access Treatment With Convalescent Plasma for the Treatment of Patients With COVID-19Status:
Product
Convalescent PlasmaClinical trial
Human Ab Response & immunoMONItoring of COVID-19 PatientsStatus: Completed, Estimated PCD: 2021-03-09
Product
Blood samples collectionProduct
CloSYS Ultra Sensitive RinseProduct
Distilled waterProduct
Listerine ZeroClinical trial
A Randomized, Observer-Blind, Dose-Escalation Phase 1 Clinical Trial of COVAC-2 in Healthy AdultsStatus: Completed, Estimated PCD: 2022-11-02
Product
COVAC-2Product
SalineClinical trial
Prevention and Treatment With Calcifediol of COVID-19 Coronavirus-induced Acute Respiratory Syndrome (SARS)Status: Completed, Estimated PCD: 2022-04-19
Product
CalcifediolProduct
BATClinical trial
Inhaled ZYESAMI (Aviptadil Acetate) for the Treatment of Severe COVID-19 (AVICOVID-3)Status: Withdrawn, Estimated PCD: 2022-06-15
Product
ZYESAMIDrug
VarlilumabClinical trial
Early Treatment of Vulnerable Individuals With Non-Severe SARS-CoV-2 Infection: A Multi-Arm Multi-Stage Randomized Trial (MAMS) to Evaluate the Effectiveness of Several Specific Treatments in Reducing the Risk of Clinical Worsening or Death in Sub-Saharan Africa (COVERAGE-Africa)Status: Recruiting, Estimated PCD: 2023-08-01
Product
Nitazoxanide and CiclésonideProduct
TelmisartanProduct
ParacetamolProduct
Fluoxetine and BudesonideClinical trial
Inhaled ZYESAMI™ for the Treatment of Severe COVID-19Status: Terminated, Estimated PCD: 2021-12-15
Clinical trial
Investigational COVID-19 Convalescent Plasma Infusion for Severely or Life-threateningly Ill COVID-19 PatientsStatus:
Product
COVID-19 Convalescent PlasmaClinical trial
A Randomized, Observer-Blind, Dose-Escalation Phase 2 Clinical Trial of COVAC-2 in Generally Healthy AdultsStatus: Completed, Estimated PCD: 2024-03-01